Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06136559




Registration number
NCT06136559
Ethics application status
Date submitted
13/11/2023
Date registered
18/11/2023
Date last updated
25/11/2024

Titles & IDs
Public title
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Scientific title
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)
Secondary ID [1] 0 0
2022-501697-19
Secondary ID [2] 0 0
1026-011
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Lymphocytic Leukemia 0 0
Small Lymphocytic Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Nemtabrutinib
Treatment: Drugs - Ibrutinib
Treatment: Drugs - Acalabrutinib

Experimental: Nemtabrutinib - Participants will receive nemtabrutinib at specified dose until disease progression, unacceptable toxicity or until discontinuation criteria are met.

Active comparator: Ibrutinib/Acalabrutinib - Participants will receive investigator's choice of ibrutinib or acalabrutinib at specified dose until disease progression, unacceptable toxicity or until discontinuation criteria are met.


Treatment: Drugs: Nemtabrutinib
Administered orally

Treatment: Drugs: Ibrutinib
Administered orally

Treatment: Drugs: Acalabrutinib
Administered orally
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective Response Rate (ORR) per Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as assessed by Blinded Independent Central Review (BICR)
Timepoint [1] 0 0
Up to ~33 months
Primary outcome [2] 0 0
Progression-Free Survival (PFS) per iwCLL Criteria 2018 as assessed by BICR
Timepoint [2] 0 0
Up to ~104 months
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to ~104 months
Secondary outcome [2] 0 0
Duration of Response (DOR) per iwCLL Criteria 2018 as assessed by BICR
Timepoint [2] 0 0
Up to ~104 months
Secondary outcome [3] 0 0
Number of Participants Who Experience One or More Adverse Events (AEs)
Timepoint [3] 0 0
Up to ~104 months
Secondary outcome [4] 0 0
Number of Participants Who Discontinue Study Treatment Due to an AE
Timepoint [4] 0 0
Up to ~104 months

Eligibility
Key inclusion criteria
The main inclusion criteria include but are not limited to the following:

* Confirmed diagnosis of CLL/SLL and active disease clearly documented to have a need to initiate therapy.
* Has at least 1 marker of disease burden.
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization.
* Has the ability to swallow and retain oral medication.
* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization.
* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening.
* Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
The main exclusion criteria include but are not limited to the following:

* Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection.
* Has gastrointestinal (GI) dysfunction that may affect drug absorption.
* Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL.
* Has had acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening.
* Has clinically significant cardiovascular disease.
* Has hypersensitivity to nemtabrutinib or contraindication to ibrutinib or acalabrutinib, or any of the excipients.
* Has history of severe bleeding disorder.
* Has history of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
* Has received any systemic anticancer therapy for CLL/SLL.
* Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors.
* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
* Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration.
* Has active infection requiring systemic therapy.
* Participants who have not adequately recovered from major surgery or have ongoing surgical complications.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/12/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/09/2032
Actual
Sample size
Target
1200
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal North Shore Hospital ( Site 2806) - St Leonards
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Iowa
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
New Jersey
Country [7] 0 0
United States of America
State/province [7] 0 0
Pennsylvania
Country [8] 0 0
United States of America
State/province [8] 0 0
Virginia
Country [9] 0 0
United States of America
State/province [9] 0 0
Washington
Country [10] 0 0
United States of America
State/province [10] 0 0
Wisconsin
Country [11] 0 0
Belgium
State/province [11] 0 0
Antwerpen
Country [12] 0 0
Belgium
State/province [12] 0 0
Vlaams-Brabant
Country [13] 0 0
Brazil
State/province [13] 0 0
Sao Paulo
Country [14] 0 0
Brazil
State/province [14] 0 0
Rio de Janeiro
Country [15] 0 0
Canada
State/province [15] 0 0
British Columbia
Country [16] 0 0
Canada
State/province [16] 0 0
Ontario
Country [17] 0 0
Canada
State/province [17] 0 0
Quebec
Country [18] 0 0
Chile
State/province [18] 0 0
Region M. De Santiago
Country [19] 0 0
China
State/province [19] 0 0
Anhui
Country [20] 0 0
China
State/province [20] 0 0
Beijing
Country [21] 0 0
China
State/province [21] 0 0
Chongqing
Country [22] 0 0
China
State/province [22] 0 0
Guangdong
Country [23] 0 0
China
State/province [23] 0 0
Guangxi
Country [24] 0 0
China
State/province [24] 0 0
Guizhou
Country [25] 0 0
China
State/province [25] 0 0
Hainan
Country [26] 0 0
China
State/province [26] 0 0
Henan
Country [27] 0 0
China
State/province [27] 0 0
Hubei
Country [28] 0 0
China
State/province [28] 0 0
Hunan
Country [29] 0 0
China
State/province [29] 0 0
Jiangsu
Country [30] 0 0
China
State/province [30] 0 0
Jiangxi
Country [31] 0 0
China
State/province [31] 0 0
Jilin
Country [32] 0 0
China
State/province [32] 0 0
Shaanxi
Country [33] 0 0
China
State/province [33] 0 0
Shandong
Country [34] 0 0
China
State/province [34] 0 0
Shanxi
Country [35] 0 0
China
State/province [35] 0 0
Sichuan
Country [36] 0 0
China
State/province [36] 0 0
Tianjin
Country [37] 0 0
China
State/province [37] 0 0
Xinjiang
Country [38] 0 0
China
State/province [38] 0 0
Zhejiang
Country [39] 0 0
Colombia
State/province [39] 0 0
Cesar
Country [40] 0 0
Colombia
State/province [40] 0 0
Cordoba
Country [41] 0 0
Colombia
State/province [41] 0 0
Valle Del Cauca
Country [42] 0 0
Czechia
State/province [42] 0 0
Hradec Kralove
Country [43] 0 0
Czechia
State/province [43] 0 0
Olomouc
Country [44] 0 0
Denmark
State/province [44] 0 0
Nordjylland
Country [45] 0 0
Denmark
State/province [45] 0 0
Sjaelland
Country [46] 0 0
Denmark
State/province [46] 0 0
Syddanmark
Country [47] 0 0
Germany
State/province [47] 0 0
Bayern
Country [48] 0 0
Germany
State/province [48] 0 0
Nordrhein-Westfalen
Country [49] 0 0
Germany
State/province [49] 0 0
Rheinland-Pfalz
Country [50] 0 0
Germany
State/province [50] 0 0
Sachsen-Anhalt
Country [51] 0 0
Germany
State/province [51] 0 0
Berlin
Country [52] 0 0
Greece
State/province [52] 0 0
Anatoliki Makedonia Kai Thraki
Country [53] 0 0
Greece
State/province [53] 0 0
Attiki
Country [54] 0 0
Greece
State/province [54] 0 0
Ioannina
Country [55] 0 0
Hong Kong
State/province [55] 0 0
Hong Kong
Country [56] 0 0
Israel
State/province [56] 0 0
Haifa
Country [57] 0 0
Israel
State/province [57] 0 0
Jerusalem
Country [58] 0 0
Israel
State/province [58] 0 0
Petah Tikva
Country [59] 0 0
Israel
State/province [59] 0 0
Ramat Gan
Country [60] 0 0
Israel
State/province [60] 0 0
Zerifin
Country [61] 0 0
Japan
State/province [61] 0 0
Aichi
Country [62] 0 0
Japan
State/province [62] 0 0
Gunma
Country [63] 0 0
Japan
State/province [63] 0 0
Hokkaido
Country [64] 0 0
Japan
State/province [64] 0 0
Hyogo
Country [65] 0 0
Japan
State/province [65] 0 0
Miyagi
Country [66] 0 0
Japan
State/province [66] 0 0
Osaka
Country [67] 0 0
Japan
State/province [67] 0 0
Shimane
Country [68] 0 0
Japan
State/province [68] 0 0
Tokyo
Country [69] 0 0
Japan
State/province [69] 0 0
Chiba
Country [70] 0 0
Japan
State/province [70] 0 0
Fukuoka
Country [71] 0 0
Japan
State/province [71] 0 0
Hiroshima
Country [72] 0 0
Japan
State/province [72] 0 0
Okayama
Country [73] 0 0
Japan
State/province [73] 0 0
Yamagata
Country [74] 0 0
Malaysia
State/province [74] 0 0
Pulau Pinang
Country [75] 0 0
New Zealand
State/province [75] 0 0
Waikato
Country [76] 0 0
New Zealand
State/province [76] 0 0
Auckland
Country [77] 0 0
Norway
State/province [77] 0 0
Akershus
Country [78] 0 0
Norway
State/province [78] 0 0
Oslo
Country [79] 0 0
Peru
State/province [79] 0 0
Ariqipa
Country [80] 0 0
Peru
State/province [80] 0 0
Lima
Country [81] 0 0
Poland
State/province [81] 0 0
Malopolskie
Country [82] 0 0
Poland
State/province [82] 0 0
Mazowieckie
Country [83] 0 0
Poland
State/province [83] 0 0
Pomorskie
Country [84] 0 0
Poland
State/province [84] 0 0
Slaskie
Country [85] 0 0
Poland
State/province [85] 0 0
Warminsko-mazurskie
Country [86] 0 0
Portugal
State/province [86] 0 0
Lisboa
Country [87] 0 0
Portugal
State/province [87] 0 0
Porto
Country [88] 0 0
South Africa
State/province [88] 0 0
Gauteng
Country [89] 0 0
South Africa
State/province [89] 0 0
Western Cape
Country [90] 0 0
Spain
State/province [90] 0 0
Barcelona
Country [91] 0 0
Spain
State/province [91] 0 0
Cataluna
Country [92] 0 0
Spain
State/province [92] 0 0
Madrid, Comunidad De
Country [93] 0 0
Spain
State/province [93] 0 0
Madrid
Country [94] 0 0
Spain
State/province [94] 0 0
Santa Cruz De Tenerife
Country [95] 0 0
Spain
State/province [95] 0 0
Salamanca
Country [96] 0 0
Sweden
State/province [96] 0 0
Stockholms Lan
Country [97] 0 0
Taiwan
State/province [97] 0 0
Kaohsiung
Country [98] 0 0
Taiwan
State/province [98] 0 0
Tainan
Country [99] 0 0
Taiwan
State/province [99] 0 0
Taipei
Country [100] 0 0
Taiwan
State/province [100] 0 0
Taoyuan
Country [101] 0 0
Thailand
State/province [101] 0 0
Chiang Mai
Country [102] 0 0
Thailand
State/province [102] 0 0
Krung Thep Maha Nakhon
Country [103] 0 0
Thailand
State/province [103] 0 0
Phitsanulok
Country [104] 0 0
Thailand
State/province [104] 0 0
Songkhla
Country [105] 0 0
Turkey
State/province [105] 0 0
Ankara
Country [106] 0 0
Turkey
State/province [106] 0 0
Edirne
Country [107] 0 0
Turkey
State/province [107] 0 0
Istanbul
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Bristol, City Of
Country [109] 0 0
United Kingdom
State/province [109] 0 0
London, City Of
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Oxfordshire
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Suffolk
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Windsor And Maidenhead
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Barnet
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Leeds

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review (BICR) and (2) nemtabrutinib is superior to ibrutinib or acalabrutinib with respect to progression free survival (PFS) per iwCLL Criteria 2018 by BICR.
Trial website
https://clinicaltrials.gov/study/NCT06136559
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Toll Free Number
Address 0 0
Country 0 0
Phone 0 0
1-888-577-8839
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06136559